Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.
As of November 2022, amoxicillin suspension has been on a national shortage list, therefore the FDA has permitted temporary compounding of amoxicillin suspensions.
People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.
By leveraging do-it-yourself testing momentum, community-based and retail pharmacies can solidify their position as health care hubs with a category management approach that enhances the consumer experience and boosts store relevance and revenue.
Sharita Howe, PharmD, discusses her recent acknowledgement by MM+M, who acknowledged her as a part of the next wave of health care leaders in their recognition of 40 under 40 leaders in health care.
Pharmacy programs are implementing new practices into their curriculum and research is being focused on mental health care.
An overview for community pharmacies of a process to minimize vaccine errors using a COVID-19 vaccine point of distribution as an example.
According to Pranav Garimella, pharmacists are essential in counseling patients with CKD on the appropriate use of semaglutide.
Piloting new emergency department-based vaccination campaigns and fine-tuning existing programs may reduce morbidity and mortality associated with vaccine-preventable diseases.
The adjuvant therapy has demonstrated varied efficacy for patients.
Case management programs or pharmacist-delivered high-touch care are critical components in medical specialty drug management.
This guide discusses the integration of continuous glucose monitoring (CGM) technology into clinical practice, emphasizing the role of pharmacists in selecting and optimizing CGM devices for patients.
Specialty pharmacists enhance CKD management through personalized care, medication adherence strategies, and collaboration with health care providers.
The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
Hospital compounding is gaining renewed attention amid drug shortages, regulatory changes, and labor challenges, prompting pharmacies to leverage advanced technology for safer, more efficient, and compliant medication preparation.
Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Amy C. Nieto explains essential guidelines for managing diabetes during Ramadan, ensuring safe fasting practices and optimal health for patients.
Shields Health Solutions poster presentations highlight a comprehensive approach to specialty patient care and successful results from an expanded offering of instructional programs.
With the increase in counterfeit GLP-1 and GLP/GIP medications available online, education may be needed for patients around the dangers of unregulated medications.
This expansion of their role goes beyond traditional dispensing duties, positioning pharmacists as an essential bridge between patients and the broader health care system.
Pharmacists have always been a vital member of the cancer care team, but the emergence of many new oral therapies is making their role in patient care a more prominent one.
As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.
In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.
There are key benefits and risks for student pharmacists to consider when approaching an Instagram account for professional pharmacy purposes.
Panelists discuss how third-line metastatic colorectal cancer treatment has evolved from limited options like FOLFOX and FOLFIRI to multiple available agents including regorafenib, trifluridine/tipiracil, trifluridine/tipiracil plus bevacizumab, and fruquintinib, emphasizing the importance of comprehensive biomarker testing to identify rare fusions and actionable targets before selecting among these therapies, each with distinct mechanisms of action and tolerability profiles that require careful sequencing and adherence management to optimize clinical outcomes.
In their concluding remarks, Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, summarize the key takeaways and highlight the persistent unmet needs in the management of hepatic encephalopathy.